Search

Displaying results 891 - 900 of 4600 in total
  1. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order … [A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally.

  2. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age.

  3. Drug

    Novobiocin

    go.drugbank.com/drugs/DB01051
    ApprovedInvestigationalVet approvedWithdrawn

    In 2009, the FDA determined novobiocin sodium was withdrawn from sale for reasons of safety or effectiveness.[L44062,L43942]

  4. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available in topical formulations for the treatment of skin infections such as athlete's foot.

  5. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market. … It was initially marketed by Pharmuka.

  6. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  7. Drug

    Tubocurarine

    go.drugbank.com/drugs/DB01199
    ApprovedWithdrawn

    [A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048] … [A216038] Tubocurarine's clinical use was limited by its relatively long duration of action (30-60 minutes)[A216038] and a number of significant side effects.

  8. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alte...

  9. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    WF10 is a chlorite-based, immunomodulating drug is developed by Nuvo Research Inc. Certain preclinical evidence and clinical pilot data suggest that WF10 may be effective in treating certain cancers. … The Corporation believes the research to-date demonstrates that WF10 acts on macrophages (a type of white blood cell) by modulating the balance between inflammation and phagocytosis, a state in which the

  10. Drug

    Desflurane

    go.drugbank.com/drugs/DB01189
    ApprovedInvestigational

    Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane. . It was developed in the late 1980s out of ...